CASI Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company providing pharmaceutical products and therapeutics to patients in China and throughout the world, has entered into framework agreements to build a  manufacturing site strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China.   The Wuxi development zone is a leading science and technology innovation center…

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China, and throughout the world, announces a strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical Co., Ltd. for the manufacturing of entecavir and cilostazol. Yiling Wanzhou International Pharmaceutical…

CASI Pharmaceuticals, Inc., a biopharmaceutical company involved in bringing pharmaceutical products to the Chinese and U.S. markets, has acquired a portfolio of 25 U.S. FDA-approved abbreviated new drug applications (ANDAs), one ANDA that FDA tentatively approved, and three ANDAs that are pending FDA approval.   CASI intends to select and commercialize certain products from the…